200 related articles for article (PubMed ID: 26142436)
1. Human Papillomavirus Vaccination of Boys and Extended Catch-up Vaccination: Effects on the Resilience of Programs.
Elfström KM; Lazzarato F; Franceschi S; Dillner J; Baussano I
J Infect Dis; 2016 Jan; 213(2):199-205. PubMed ID: 26142436
[TBL] [Abstract][Full Text] [Related]
2. Benefits of catch-up in vaccination against human papillomavirus in medium- and low-income countries.
Baussano I; Lazzarato F; Ronco G; Dillner J; Franceschi S
Int J Cancer; 2013 Oct; 133(8):1876-81. PubMed ID: 23564420
[TBL] [Abstract][Full Text] [Related]
3. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from a systematic review.
Mahumud RA; Alam K; Keramat SA; Ormsby GM; Dunn J; Gow J
PLoS One; 2020; 15(6):e0233499. PubMed ID: 32484811
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of human papillomavirus in teenage heterosexual males following the implementation of female and male school-based vaccination in Australia: 2014-2017.
Chow EPF; Tabrizi SN; Fairley CK; Wigan R; Machalek DA; Regan DG; Hocking JS; Garland SM; Cornall AM; Atchison S; Bradshaw CS; McNulty A; Owen L; Marshall L; Russell DB; Kaldor JM; Chen MY
Vaccine; 2019 Oct; 37(46):6907-6914. PubMed ID: 31562001
[TBL] [Abstract][Full Text] [Related]
6. Is expanding HPV vaccination programs to include school-aged boys likely to be value-for-money: a cost-utility analysis in a country with an existing school-girl program.
Pearson AL; Kvizhinadze G; Wilson N; Smith M; Canfell K; Blakely T
BMC Infect Dis; 2014 Jun; 14():351. PubMed ID: 24965837
[TBL] [Abstract][Full Text] [Related]
7. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
Cody P; Tobe K; Abe M; Elbasha EH
BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
[TBL] [Abstract][Full Text] [Related]
8. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis.
Drolet M; Bénard É; Boily MC; Ali H; Baandrup L; Bauer H; Beddows S; Brisson J; Brotherton JM; Cummings T; Donovan B; Fairley CK; Flagg EW; Johnson AM; Kahn JA; Kavanagh K; Kjaer SK; Kliewer EV; Lemieux-Mellouki P; Markowitz L; Mboup A; Mesher D; Niccolai L; Oliphant J; Pollock KG; Soldan K; Sonnenberg P; Tabrizi SN; Tanton C; Brisson M
Lancet Infect Dis; 2015 May; 15(5):565-80. PubMed ID: 25744474
[TBL] [Abstract][Full Text] [Related]
9. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
Armstrong EP
J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
[TBL] [Abstract][Full Text] [Related]
10. Gender-neutrality, herd effect and resilient immune response for sustainable impact of HPV vaccination.
Lehtinen M; Apter D
Curr Opin Obstet Gynecol; 2015 Oct; 27(5):326-32. PubMed ID: 26308204
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour.
Wolff E; Elfström KM; Haugen Cange H; Larsson S; Englund H; Sparén P; Roth A
Vaccine; 2018 Aug; 36(34):5160-5165. PubMed ID: 30017146
[TBL] [Abstract][Full Text] [Related]
12. Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe.
Marty R; Roze S; Bresse X; Largeron N; Smith-Palmer J
BMC Cancer; 2013 Jan; 13():10. PubMed ID: 23298365
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus vaccine coverage in Rwanda: A population-level analysis by birth cohort.
Sayinzoga F; Umulisa MC; Sibomana H; Tenet V; Baussano I; Clifford GM
Vaccine; 2020 May; 38(24):4001-4005. PubMed ID: 32336599
[TBL] [Abstract][Full Text] [Related]
14. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
Patel C; Brotherton JM; Pillsbury A; Jayasinghe S; Donovan B; Macartney K; Marshall H
Euro Surveill; 2018 Oct; 23(41):. PubMed ID: 30326995
[TBL] [Abstract][Full Text] [Related]
15. Too late to vaccinate? The incremental benefits and cost-effectiveness of a delayed catch-up program using the 4-valent human papillomavirus vaccine in Norway.
Burger EA; Sy S; Nygård M; Kristiansen IS; Kim JJ
J Infect Dis; 2015 Jan; 211(2):206-15. PubMed ID: 25057044
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus (HPV) vaccination: from clinical studies to immunization programs.
Murillo R; Ordóñez-Reyes C
Int J Gynecol Cancer; 2019 Oct; 29(8):1317-1326. PubMed ID: 31455660
[TBL] [Abstract][Full Text] [Related]
17. Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III).
Lehtinen M; Luostarinen T; Vänskä S; Söderlund-Strand A; Eriksson T; Natunen K; Apter D; Baussano I; Harjula K; Hokkanen M; Kuortti M; Palmroth J; Petäjä T; Pukkala E; Rekonen S; Siitari-Mattila M; Surcel HM; Tuomivaara L; Paavonen J; Nieminen P; Dillner J; Dubin G; Garnett G
Int J Cancer; 2018 Nov; 143(9):2299-2310. PubMed ID: 29845626
[TBL] [Abstract][Full Text] [Related]
18. Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK.
Datta S; Pink J; Medley GF; Petrou S; Staniszewska S; Underwood M; Sonnenberg P; Keeling MJ
BMC Infect Dis; 2019 Jun; 19(1):552. PubMed ID: 31234784
[TBL] [Abstract][Full Text] [Related]
19. The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia.
Smith MA; Lew JB; Walker RJ; Brotherton JM; Nickson C; Canfell K
Vaccine; 2011 Nov; 29(48):9112-22. PubMed ID: 21419773
[TBL] [Abstract][Full Text] [Related]
20. Potential lives saved in 73 countries by adopting multi-cohort vaccination of 9-14-year-old girls against human papillomavirus.
Jit M; Brisson M
Int J Cancer; 2018 Jul; 143(2):317-323. PubMed ID: 29446090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]